AAV RPGR gene therapy - NightstaRx

Drug Profile

AAV RPGR gene therapy - NightstaRx

Alternative Names: AAV XLRPGR; AAV-RPGR; AAV-XLRPGR gene therapy; NSR AAV-RPGR; NSR-RPGR

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Innovation; University of Oxford
  • Developer NightstaRx
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Retinitis pigmentosa

Most Recent Events

  • 19 Mar 2017 Phase-I/II clinical trials in Retinitis pigmentosa in United Kingdom (Intraocular)
  • 18 Mar 2017 Preclinical trials in Retinitis pigmentosa in United Kingdom (Intraocular)
  • 01 Mar 2017 The UK Medicines and Healthcare Products Agency (MHRA) approves Clinical trial application for phase I/II trial of AAV RPGR gene therapy in Retinitis pigmentosa before March 2017 (NightstaRx pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top